Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) EVP Sells $200,000.00 in Stock

Posted by Defense World Staff on Apr 15th, 2023

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) EVP Yakob Liawatidewi sold 5,000 shares of the firm’s stock in a transaction dated Monday, April 10th. The shares were sold at an average price of $40.00, for a total value of $200,000.00. Following the transaction, the executive vice president now owns 69,215 shares in the company, valued at $2,768,600. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Yakob Liawatidewi also recently made the following trade(s):

On Thursday, April 13th, Yakob Liawatidewi sold 11,494 shares of Amphastar Pharmaceuticals stock. The shares were sold at an average price of $41.56, for a total value of $477,690.64.

Amphastar Pharmaceuticals Trading Up 0.7 %

Amphastar Pharmaceuticals stock opened at $42.15 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.90 and a current ratio of 3.99. The business’s 50-day simple moving average is $35.71 and its 200-day simple moving average is $31.40. The firm has a market capitalization of $2.02 billion, a PE ratio of 23.95 and a beta of 0.76. Amphastar Pharmaceuticals, Inc. has a 52 week low of $26.76 and a 52 week high of $42.35.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Dakota Wealth Management bought a new position in shares of Amphastar Pharmaceuticals in the first quarter worth about $203,000. Raymond James & Associates increased its stake in shares of Amphastar Pharmaceuticals by 2.1% in the first quarter. Raymond James & Associates now owns 23,561 shares of the company’s stock worth $884,000 after purchasing an additional 483 shares during the period. Exchange Traded Concepts LLC increased its stake in shares of Amphastar Pharmaceuticals by 25.4% in the first quarter. Exchange Traded Concepts LLC now owns 46,583 shares of the company’s stock worth $1,747,000 after purchasing an additional 9,431 shares during the period. Everence Capital Management Inc. bought a new position in shares of Amphastar Pharmaceuticals in the first quarter worth about $243,000. Finally, Truist Financial Corp increased its stake in shares of Amphastar Pharmaceuticals by 260.3% in the fourth quarter. Truist Financial Corp now owns 28,568 shares of the company’s stock worth $800,000 after purchasing an additional 20,640 shares during the period. 61.72% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday.

About Amphastar Pharmaceuticals

(Get Rating)

Amphastar Pharmaceuticals, Inc engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments.